- Home
- CAPS vs PHIO Comparison
CAPS vs PHIO Comparison
Compare CAPS & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPS
- PHIO
- Stock Information
- Founded
- CAPS 1987
- PHIO 2011
- Country
- CAPS United States
- PHIO United States
- Employees
- CAPS N/A
- PHIO N/A
- Industry
- CAPS
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CAPS
- PHIO Health Care
- Exchange
- CAPS NYSE
- PHIO Nasdaq
- Market Cap
- CAPS 9.8M
- PHIO 8.6M
- IPO Year
- CAPS N/A
- PHIO N/A
- Fundamental
- Price
- CAPS $1.86
- PHIO $2.96
- Analyst Decision
- CAPS
- PHIO Strong Buy
- Analyst Count
- CAPS 0
- PHIO 2
- Target Price
- CAPS N/A
- PHIO $9.00
- AVG Volume (30 Days)
- CAPS 1.2M
- PHIO 701.6K
- Earning Date
- CAPS 04-02-2025
- PHIO 05-15-2025
- Dividend Yield
- CAPS N/A
- PHIO N/A
- EPS Growth
- CAPS N/A
- PHIO N/A
- EPS
- CAPS N/A
- PHIO N/A
- Revenue
- CAPS $43,416,000.00
- PHIO N/A
- Revenue This Year
- CAPS $7.87
- PHIO N/A
- Revenue Next Year
- CAPS N/A
- PHIO N/A
- P/E Ratio
- CAPS N/A
- PHIO N/A
- Revenue Growth
- CAPS N/A
- PHIO N/A
- 52 Week Low
- CAPS $1.58
- PHIO $0.97
- 52 Week High
- CAPS $16.18
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CAPS N/A
- PHIO 77.11
- Support Level
- CAPS N/A
- PHIO $1.71
- Resistance Level
- CAPS N/A
- PHIO $2.08
- Average True Range (ATR)
- CAPS 0.00
- PHIO 0.18
- MACD
- CAPS 0.00
- PHIO 0.09
- Stochastic Oscillator
- CAPS 0.00
- PHIO 84.46
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.